Search clinical trials for: CHF5633

Total 13 results

Chiesi Farmaceutici S.p.A.

Recruiting

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis

Bronchiectasis

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Investigate the Safety, Tolerability and Pharmacokinetics of CHF6523 in Healthy and in COPD Subjects (CHF6523)

COPD

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

First In Human Study on Synthetic Surfactant CHF 5633 in Respiratory Distress Syndrome

Respiratory Distress Syndrome in Premature Infants

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)

Respiratory Distress Syndrome, Newborn

United States
Chiesi Farmaceutici S.p.A.

Completed

A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects (CHF6333 FIH)

Cystic Fibrosis | Non-Cystic Fibrosis Bronchiectasis

Belgium
Chiesi Farmaceutici S.p.A.

Terminated

CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome (NOWSHINE)

Neonatal Opioid Withdrawal Syndrome

United States
Chiesi Farmaceutici S.p.A.

Recruiting

Comparison Between CHF5993 pMDI 200/6/12,5mg HFA-152a VS CHF5993 pMDI 200/6/12,5mg HFA-134a in Subjects With Asthma (Trecos) (TRECOS)

Asthma

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD (TRIFORCE)

Chronic Obstructive Pulmonary Disease

Germany
Chiesi Farmaceutici S.p.A.

Completed

Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD) (TRI-D)

Chronic Obstructive Pulmonary Disease

Bulgaria
Chiesi Farmaceutici S.p.A.

Completed

Drug-drug Interaction Study of CHF5993 With Cimetidine

COPD

Belgium
Chiesi Farmaceutici S.p.A.

Completed

A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

United States
Chiesi Farmaceutici S.p.A.

Completed

Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients (TRIPLE 4)

COPD

Poland
Chiesi Farmaceutici S.p.A.

Completed

Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients

Chronic Obstructive Pulmonary Disease | Asthma

3

Subscribe